165948-23-2

Basic information

• Product Name: 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDINE HYDROCHLORIDE SALT
• Synonyms: 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDINE HYDROCHLORIDE SALT;4,5,6,7-Tetrahydrothiazolo[5,4-c]pyridine hydrochloride;4,5,6,7-TETRAHYDRO[1,3]THIAZOLO[5,4-C]PYRIDINE;4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine;Thiazolo[5,4-c]pyridine,4,5,6,7-tetrahydro-;4,5,6,7-Teterahydrothiazolo[5,4-c]pyridine
• CAS NO: 165948-23-2
• Molecular Formula: C6H9ClN2S
• Molecular Weight: 176.66706
• Mol File: 165948-23-2.mol

Chemical Properties

• Boiling Point: 367 °C at 760 mmHg
• Flash Point: 175.7 °C
• Appearance: /
• Density: 1.219±0.06 g/cm3(Predicted)
• PKA: 7.88±0.20(Predicted)
• CAS DataBase Reference: 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDINE HYDROCHLORIDE SALT(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDINE HYDROCHLORIDE SALT(165948-23-2)
• EPA Substance Registry System: 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDINE HYDROCHLORIDE SALT(165948-23-2)

Safety Data

• Hazardous Substances Data: 165948-23-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDINE HYDROCHLORIDE SALT is used as a pharmaceutical agent for its potential to act as an antagonist or agonist at specific receptor sites in the body, contributing to the modulation of various biological processes and therapeutic effects.
Used in Organic Synthesis:
4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDINE HYDROCHLORIDE SALT is utilized as a key intermediate in the synthesis of complex organic molecules, facilitating the development of novel compounds with diverse applications in various fields.
Used in Chemical Research:
The unique chemical structure of 4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDINE HYDROCHLORIDE SALT makes it an intriguing subject for further study, enabling researchers to explore its properties, reactivity, and potential applications in drug development and other chemical processes.

InChI:InChI=1/C6H8N2S.ClH/c1-2-7-3-6-5(1)8-4-9-6;/h4,7H,1-3H2;1H

Upstream product

• 165948-22-1 5-Ethoxycarbonyl-4,5,6,7-tetrahydrothiazolo[5,4-c]-pyridine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 188869-05-8 tert-butyl 3-bromo-4-oxo-piperidine-1-carboxylate 
• 365996-05-0 tert-butyl 2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate 
• 365996-06-1 2-Bromo-5-tert-butoxycarbonyl-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine 
• 165948-24-3 5-tert-Butoxycarbonyl-4,5,6,7-tetrahydrothiazolo[5,4-c]-pyridine 
• 89424-04-4 3-chloro-1-ethoxycarbonyl-4-piperidone 

Downstream Products

• 165948-24-3 5-tert-Butoxycarbonyl-4,5,6,7-tetrahydrothiazolo[5,4-c]-pyridine 
• 758685-72-2 5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxylic acid 

Relevant articles and documents

Substituted oxazolidinone compounds and method and use thereof

The invention provides a substituted oxazolidinone compound represented by a formula (I) shown in specifications, or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof. The compound i

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof:wherein Y1 is of formula (?) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V4, V5, Rx, x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine derivatives

In our investigation of factor Xa inhibitors, a series of 1-(6-chloronaphthalen-2-yl)sulfonyl-4-(4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine-2-carbonyl)piperazines 3a-i were synthesized. In vitro inhibitory activities of the compounds against factor Xa and coagulation are summarized. Among the compounds, 3c and 3d, possessing a carbamoyl or N-methylcarbamoyl moiety, showed potent inhibitory activities when administered orally to rats.

Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element

Our exploratory study was based on the concept that a non-amidine factor Xa (fXa) inhibitor is suitable for an orally available anticoagulant. We synthesized and evaluated a series of N-(6-chloronaphthalen-2-yl) sulfonylpiperazine derivatives incorporating various fused-bicyclic rings containing an aliphatic amine expected to be S4 binding element. Among this series, 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine type 61 displayed orally potent anti-fXa activity and evident prolongation of prothrombin time (PT) with the moderate bioavailability in rats. The X-ray crystal analysis afforded an obvious binding mode that 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine and 6-chloronaphthalene respectively bound to S4 and S1 subsites. In this X-ray study, we discovered a novel intramolecular S-O close contact. Ab initio energy calculations of model compounds deduced that conformers with the most close S-O proximity were most stable. The Mulliken population analysis proposed that this energy profile was caused by both of electrostatic S-O affinity and N-O repulsion. The results of these calculations and X-ray analysis suggested a possibility that the restricted conformation effected the affinity to S4 subsite of fXa.

Compound with platelet aggregation inhibitor activity

A compound represented by the general formula (I) and a pharmaceutically acceptable salt and solvate thereof having an effect for inhibiting the agglutination of platelets is disclosed: STR1 wherein R1 represents a group --W--(CH2)i --COOR3, R2 represents a hydrogen atom or a group --W--(CH2)i --COOR3 or --OR4, X represents --CH= or --N=, Y represents (i) a group --(CO)k --N(R5)--Z--, wherein Z represents a bond or a group --(CH2)m --CO-- or a group --(CH2)m --CHR6 --, (ii) a group --(CH2)m --N(R5)--(CO)k --, or (iii) a group --(CO)k -Het, wherein Het represents a five- or six-membered heterocyclic ring comprising a nitrogen atom, A represents (i) the following groups (III) or (IV) STR2 B represents a bond, C1-6 alkylene or C2-6 alkenylen.